Berglind Jonsdottir1, Christer Larsson2, Annelie Carlsson3, Gun Forsander4, Sten Anders Ivarsson1, Åke Lernmark1, Johnny Ludvigsson5, Claude Marcus6, Ulf Samuelsson5, Eva Örtqvist7, Helena Elding Larsson1. 1. Department of Clinical Sciences, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden. 2. Department of Laboratory Medicine, Lund University, SE-211 85 Lund, Sweden. 3. Department of Pediatrics, Lund University, Skåne University Hospital, SE-211 85 Lund, Sweden. 4. Department of Pediatrics, The Queen Silvia Children's Hospital, SE-416 86 Gothenburg, Sweden. 5. Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping University Hospital, SE-58183 Linköping, Sweden. 6. Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institute, SE-171 77 Stockholm, Sweden. 7. Pediatric Endocrinology Unit, Department of Women's and Children's Health, Karolinska Institute, SE-171 77 Stockholm, Sweden.
Abstract
Context: Screening of autoimmune thyroid disease in children with type 1 diabetes is important but varies between clinics. Objective: To determine the predictive value of thyroid autoantibodies, thyroid function, islet autoantibodies, and HLA-DQ at diagnosis of type 1 diabetes for autoimmune thyroid disease during follow-up. Setting: Forty-three Swedish pediatric endocrinology units. Design, Patients, and Main Outcome Measures: At diagnosis of type 1 diabetes, autoantibodies against thyroid peroxidase (TPOAb), thyroglobulin (TGAb), glutamic acid decarboxylase (GADA), insulin, insulinoma-associated protein-2, and 3 variants of zinc transporter 8 (ZnT8W/R/QA) HLA-DQA1-B1 genotypes and thyroid function were analyzed in 2433 children. After 5.1 to 9.5 years, information on thyroxine treatment was gathered from the Swedish National Board of Health and Welfare's Prescribed Drug Register. Results: Thyroxine was prescribed to 6% of patients. In patients <5 years of age, female sex [hazard ratio (HR) = 4.60; P = 0.008] and GADA (HR = 5.80; P = 0.02) were predictors. In patients 5 to 10 years old, TPOAb (HR = 20.56; P < 0.0001), TGAb (HR = 3.40; P = 0.006), and thyroid-stimulating hormone (TSH) (HR = 3.64; P < 0.001) were predictors, whereas in 10 to 15 year olds, TPOAb (HR = 17.00; P < 0.001) and TSH (HR = 4.11; P < 0.001) predicted thyroxine prescription. Conclusion: In addition to TPOAb and TSH, GADA at diagnosis of type 1 diabetes is important for the prediction of autoimmune thyroid disease in children <5 years of age.
Context: Screening of autoimmune thyroid disease in children with type 1 diabetes is important but varies between clinics. Objective: To determine the predictive value of thyroid autoantibodies, thyroid function, islet autoantibodies, and HLA-DQ at diagnosis of type 1 diabetes for autoimmune thyroid disease during follow-up. Setting: Forty-three Swedish pediatric endocrinology units. Design, Patients, and Main Outcome Measures: At diagnosis of type 1 diabetes, autoantibodies against thyroid peroxidase (TPOAb), thyroglobulin (TGAb), glutamic acid decarboxylase (GADA), insulin, insulinoma-associated protein-2, and 3 variants of zinc transporter 8 (ZnT8W/R/QA) HLA-DQA1-B1 genotypes and thyroid function were analyzed in 2433 children. After 5.1 to 9.5 years, information on thyroxine treatment was gathered from the Swedish National Board of Health and Welfare's Prescribed Drug Register. Results:Thyroxine was prescribed to 6% of patients. In patients <5 years of age, female sex [hazard ratio (HR) = 4.60; P = 0.008] and GADA (HR = 5.80; P = 0.02) were predictors. In patients 5 to 10 years old, TPOAb (HR = 20.56; P < 0.0001), TGAb (HR = 3.40; P = 0.006), and thyroid-stimulating hormone (TSH) (HR = 3.64; P < 0.001) were predictors, whereas in 10 to 15 year olds, TPOAb (HR = 17.00; P < 0.001) and TSH (HR = 4.11; P < 0.001) predicted thyroxine prescription. Conclusion: In addition to TPOAb and TSH, GADA at diagnosis of type 1 diabetes is important for the prediction of autoimmune thyroid disease in children <5 years of age.
Authors: Guillermo E Umpierrez; Kashif A Latif; Mary Beth Murphy; Helen C Lambeth; Frankie Stentz; Andrew Bush; Abbas E Kitabchi Journal: Diabetes Care Date: 2003-04 Impact factor: 19.112
Authors: Nicolas Rodondi; Wendy P J den Elzen; Douglas C Bauer; Anne R Cappola; Salman Razvi; John P Walsh; Bjørn O Asvold; Giorgio Iervasi; Misa Imaizumi; Tinh-Hai Collet; Alexandra Bremner; Patrick Maisonneuve; José A Sgarbi; Kay-Tee Khaw; Mark P J Vanderpump; Anne B Newman; Jacques Cornuz; Jayne A Franklyn; Rudi G J Westendorp; Eric Vittinghoff; Jacobijn Gussekloo Journal: JAMA Date: 2010-09-22 Impact factor: 56.272
Authors: B Jonsdottir; C Andersson; A Carlsson; A Delli; G Forsander; J Ludvigsson; C Marcus; U Samuelsson; E Ortqvist; A Lernmark; S-A Ivarsson; H Elding Larsson Journal: Diabetologia Date: 2013-05-12 Impact factor: 10.122
Authors: Jacqueline A Gardner; Randi K Johnson; Fran Dong; Michelle Hoffman; Andrea K Steck; Brigitte I Frohnert; Marian Rewers; Jill M Norris Journal: Endocrine Date: 2020-07-10 Impact factor: 3.633
Authors: Berglind Jonsdottir; Markus Lundgren; Sara Wallengren; Åke Lernmark; Ida Jönsson; Helena Elding Larsson Journal: Eur Thyroid J Date: 2017-09-19
Authors: Jane L Chiang; David M Maahs; Katharine C Garvey; Korey K Hood; Lori M Laffel; Stuart A Weinzimer; Joseph I Wolfsdorf; Desmond Schatz Journal: Diabetes Care Date: 2018-08-09 Impact factor: 19.112
Authors: Robert Z Harms; Katie R Ostlund; Monina S Cabrera; Earline Edwards; Marisa Fisher; Nora Sarvetnick Journal: Front Immunol Date: 2020-09-15 Impact factor: 7.561